- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02939924
Treatment of Patients With Lesions in the Superficial Femoral and/ or Popliteal Arteries Using Kanshas Paclitaxel-coated Balloon Catheter. (KANSHAS-1)
Prospective, Multi-Center, Open, Single Arm Study for the Treatment of Patients Presenting De Novo Lesions in the Superficial Femoral and/or Popliteal Arteries Using a Kanshas Drug Coated Balloon Catheter.
Study Overview
Status
Intervention / Treatment
Detailed Description
The KANSHAS 1 (K-1) trial investigates the inhibition of restenosis using the Kanshas Paclitaxel-coated Balloon Catheter in the treatment of de novo lesions in the superficial femoral and/or popliteal arteries.
This clinical study is a prospective, multi-center, open, single-arm study. Up to 50 patients will be enrolled at 2 sites in Belgium and 4 sites in Germany. Follow-ups are scheduled before discharge, at 1 month (Clinic Visit or Phone FU), 6 months, 1-year, 2-years (Clinic Visits), 3-, 4- and 5- years (Clinic Visits or Phone FU).
Primary outcome measure:
- freedom from device-and procedure-related death through 30 days.
- freedom from target limb amputations and clinically driven target lesion revascularization through 6 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General:
- Clinically significant symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery;
- Able and willing to provide informed consent prior to study procedures;
- Able and willing to comply with follow-up requirements;
- Rutherford Clinical Category of 2-4;
- Resting ABI of <0.9 or abnormal exercise ABI;
- ≥18 years old;
Life expectancy is >2 year;
Angiographic Criteria:
Cumulative lesion length ≥4 and ≤15 cm within the target vessel; Cumulative lesion consists of either a single de novo lesion or multiple lesions within the 4-15 cm segment; multiple lesions require to meet all the following;
- Separated by a gap of ≤ 3 cm;
- Able to be treated as a single lesion;
- Total combined lesion length including 3cm gap meets requirements;
- Lesion location starts ≥2 cm distal to the common femoral bifurcation and terminates at ≥2 cm proximal to the origin of the tibio-peroneal trunk;
- Clinically and hemodynamically significant de novo stenosis (>70% stenosis by visual estimate) or occlusion;
- Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix;
- Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion;
- A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of ipsilateral iliac lesions); NOTE: Successful ipsilateral iliac artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication.
- At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been revascularized;
Exclusion Criteria:
- Pregnant or lactating females;
- Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries;
- Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy;
- Known intolerance to study medications, paclitaxel or contrast agents;
- Patient participating in another investigational device or drug study that has not reached the primary endpoint;
- History of hemorrhagic stroke within 2 months;
- Previous or planned surgical or interventional procedure within 30 days of the study procedure;
- Diagnosed liver failure, renal failure, chronic kidney disease, unstable angina pectoris, or myocardial infarction within 30 days of the procedure;
- Presence of significant stenosis or occlusion of the inflow tract that cannot be successfully treated prior to study consideration. Successful is defined as <30% residual stenosis of ipsilateral iliac artery with no major complications;
- Acute thrombus in target vessel;
- At site of target lesion, use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, brachytherapy);
- Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (≥50% stenosis) may not be treated during the same procedure;
- Has in-stent restenosis in the target lesion;
- Previous treatment with a drug coated PTA balloon catheter or drug eluting stent in the target vessel within 12 months of the index procedure;
- Previous peripheral bypass affecting the target limb;
- Has injuries in the target vessel, such as major flow-limiting dissection ( > NHLBI Grade C) and perforation, requiring stenting prior to enrollment;
- Obvious subintimal recanalization or intentional subintimal recanalization in the occlusive lesions;
- Presence of severe calcification in the target lesions that precludes endovascular treatment. Severe calcification is defined as circumferential calcification involving ≥ 50% of vessel diameter.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DCB treatment
Patient treated with Kanshas DCB
|
The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length.
The balloons is sized to ensure the full length of the lesion is treated.
The initial inflation of the study device should be approximately 1 minute for optimal drug release.
In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome measure of the study is a composite of freedom from device and procedure related deaths through 30 days, freedom from target limb amputation, and clinically driven target lesion revascularization (TLR) through 6 months.
Time Frame: 6 months
|
Clinically-driven target lesion revascularization is defined as a restenosis of 50% or more in the target lesion with worsening symptoms, OR more as 70% stenosis without symptoms.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Lichtenberg, MD, Karolinen-Hospital Klinikum Arnsberg, Germany
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T129E4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterSociety for Vascular SurgeryCompletedPeripheral Artery Disease (PAD)United States
Clinical Trials on Kanshas DCB
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruiting
-
Acotec Scientific Co., LtdShanghai Tongji Hospital, Tongji University School of MedicineRecruiting
-
C. R. BardCompletedFemoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal ArteriesChina
-
ReFlow Medical, Inc.Massachusetts General Hospital; Syntropic CorelabCompletedCritical Limb IschemiaDominican Republic
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioEnrolling by invitation
-
VitNovo, Inc.Completed
-
National Taiwan University HospitalTaipei Veterans General Hospital, Taiwan; Development Center for Biotechnology... and other collaboratorsUnknownDementia, Alzheimer TypeTaiwan
-
Acotec Scientific Co., LtdRecruitingStenosis of Native Hemodialysis Arteriovenous FistulasChina
-
Henan Institute of Cardiovascular EpidemiologyRecruiting